Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial of Ataciguat, Advances Plans for Aortic Stenosis Development Kardigan®, Inc., a precision cardiovascular company, has announced the completion of enrollment in its…
Bristol Myers Squibb Presents 56-Week SCOUT-HCM Results Supporting Camzyos in Pediatric Patients With Obstructive Hypertrophic Cardiomyopathy Bristol Myers Squibb has announced positive 56-week results from the Phase 3 SCOUT-HCM clinical…
Lenacapavir Achieves Nearly Twice the One-Year Persistence of Daily Oral F/TDF for HIV Prevention Gilead Sciences, has announced positive results from its PURPOSE 5 clinical trial, demonstrating significantly higher persistence…
Obsidian Therapeutics Reports Promising Amsoki-Cel Results in ICI-Resistant Advanced Melanoma, With 67% Response Rate Obsidian Therapeutics, a clinical-stage biopharmaceutical company developing engineered tumor-infiltrating lymphocyte (TIL) cell therapies through its proprietary…
Aulos Bioscience Reports Positive Phase 2 Results for Imneskibart-Based Regimens in Checkpoint Inhibitor-Refractory Melanoma and NSCLC at SITC 2026 Aulos Bioscience, an immuno-oncology company focused on developing innovative immune-activating antibody…
Onchilles Pharma Presents Preliminary Clinical Findings for N17350, an Investigational Intratumoral Cancer Therapy, at SITC 2026 Onchilles Pharma, a clinical-stage biotechnology company developing next-generation cancer therapies targeting the ELANE pathway,…
Agenus Reports Long-Term Survival Benefits with Botensilimab and Balstilimab Combination in MSS Metastatic Colorectal Cancer at SITC 2026 Agenus Inc., a biotechnology company focused on developing innovative immuno-oncology treatments, has…
Indapta Therapeutics to Present Complete Phase 1 Data for IDP-023 Combination Therapy in Relapsed/Refractory Multiple Myeloma at SITC 2026 Indapta Therapeutics, Inc., a privately held clinical-stage biotechnology company focused on…
Front Range Pharmaceuticals Receives FDA Fast Track Designation for FRP-003 to Treat Long COVID Front Range Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has granted Fast…
Pulse Biosciences Reports Encouraging Six-Month PRECISE-BTN Study Results for nPulse Vybrance System in Benign Thyroid Nodules Pulse Biosciences, Inc., a medical technology company developing its proprietary Nanosecond Pulsed Field Ablation™…
MaaT Pharma Reports Preliminary Phase 2a PICASSO Trial Findings Evaluating MaaT013 in Combination With Immunotherapy for Advanced Melanoma MaaT Pharma, a late-stage clinical biotechnology company and a leader in the…
Revelation Biosciences Reports Third Quarter 2026 Financial Results, Highlights Gemini Development and $94 Billion Market Opportunity Revelation Biosciences, Inc., a clinical-stage life sciences company focused on developing innovative therapeutic solutions…